Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Apr 1, 2015
NEWTON, Mass., April 1, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Mikael Dolsten, MD, PhD,...
-
Mar 18, 2015
NEWTON, Mass., March 18, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that five abstracts describing the company's...
-
Mar 18, 2015
NEWTON, Mass., March 18, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that fourteen abstracts describing the...
-
Mar 16, 2015Initiated Multiple Registration-directed Trials and Presented Positive Selinexor Clinical Data in 2014
NEWTON, Mass., March 16, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the fourth quarter and...
-
Mar 9, 2015
NEWTON, Mass., March 9, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and year...
-
Feb 23, 2015Research Conducted in Collaboration with Mount Sinai with Funding from the National Multiple Sclerosis Society and from the National Institute for Neurological Disorders and Stroke
NEWTON, Mass., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Nature Neuroscience published data...
-
Feb 5, 2015
NEWTON, Mass., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that Michael G. Kauffman, MD, PhD, Chief...
-
Jan 8, 2015
NEWTON, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that its lead drug candidate, selinexor...
-
Jan 7, 2015
NEWTON, Mass., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that Michael G. Kauffman, MD, PhD, Chief...
-
Jan 6, 2015
NEWTON, Mass., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock...